Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial

Value in Health

Volumn 15, Issue 2, 2012, Pages 255-260

  Shiroiwa, Takeru ^a   Takeuchi, Toshihiro ^b   Fukuda, Takashi ^b   Shimozuma, Kojiro ^a   Ohashi, Yasuo ^b  

^a RITSUMEIKAN UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

adjuvant drug therapy; colon cancer; cost effectiveness; FOLFOX regimen; oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ARTICLE; COLON CANCER; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; JAPAN; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; FINANCING, PERSONAL; FLUOROURACIL; HEALTH CARE COSTS; HUMANS; JAPAN; LEUCOVORIN; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS;

EID: 84858654122     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.10.006     Document Type: Article

References (21)

1. Ministry of Health, Labour and Welfare. Population Survey Report [in Japanese]. Tokyo: Ministry of Health, Labour and Welfare, 2009.
2. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet 2010;375:1030-47.
3. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44.
4. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorinmodulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:1879-87. (Pubitemid 23304611)
5. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999;17:3553-9. (Pubitemid 29517927)
6. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47. (Pubitemid 30644117)
7. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350: 2343-51. (Pubitemid 38702845)
8. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:2198-204. (Pubitemid 46954643)
9. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16.
10. Eggington S, Tappenden P, Pandor A, et al. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer 2006;95:1195-201. (Pubitemid 44658483)
11. Aballea S, Chancellor JV, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 2007;109: 1082-9. (Pubitemid 46435386)
12. Attard CL, Maroun JA, Alloul K, et al. Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada. Curr Oncol 2010; 17:17-24.
13. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-8. (Pubitemid 26337709)
14. Shiroiwa T, Fukuda T, Tsutani K. Health utility scores of colorectal cancer based on societal preference in Japan. Qual Life Res 2009;18: 1095-103.
15. Social Insurance Research Laboratory. Reimbursement Schedule of National Health Insurance [in Japanese]. Tokyo: Social Insurance Research Laboratory, 2010.
16. Jiho. Standard Drug Price of National Health Insurance [in Japanese]. Tokyo: Jiho, 2010.
17. Lin D, Feuer E, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics 1997;53:419-34. (Pubitemid 27262208)
18. Boag JW. Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J RStat Soc B 1949;11:15-53.
19. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: National Institute for Health and Clinical Excellence, 2008.
20. Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010;19:422-37.
21. National Institute for Health and Clinical Excellence. Technology Appraisal 100. Capecitabine and oxaliplatinin the adjuvant treatment of stage III (Dukes'C) colon cancer. London: National Institute for Health and Clinical Excellence, 2006.